Summary: Stanford professor James Zou is reportedly raising approximately $100 million at a valuation targeting $1 billion for a startup called Human Intelligence that applies AI to research on the human body, according to Bloomberg. Zou’s research includes an FDA-cleared cardiac AI (EchoNet), a Nature-published Virtual Lab that designed novel nanobodies, and a Virtual Biotech […]<br /> This story continues at The Next Web [...]
AI agents are now embedded in real enterprise workflows, and they're still failing roughly one in three attempts on structured benchmarks. That gap between capability and reliability is the defin [...]
Some of the most successful creators on Facebook aren't names you'd ever recognize. In fact, many of their pages don't have a face or recognizable persona attached. Instead, they run pa [...]
HeartFocus, the AI-powered cardiac imaging software developed by French medtech company DESKi, has launched HeartFocus Link, a product that connects a tablet to any cart-based ultrasound system throug [...]
The FDA has launched the generative AI tool, Elsa, agency-wide to help its employees with everything from clinical reviews to investigations. Sure, we're living in a time of widespread disinforma [...]
At the start of the month, Elon Musk announced that two of his companies — SpaceX and xAI — were merging, and would jointly launch a constellation of 1 million satellites to operate as orbital d [...]
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science a [...]
In a few short days, jury selection will begin in the long-awaited Musk v. Altman case. At the end of that process, an Oakland federal court will task nine regular people with deciding if OpenAI defra [...]
Current and former members of the FDA told CNN about issues with the Elsa generative AI tool unveiled by the federal agency last month. Three employees said that in practice, Elsa has hallucinated non [...]
Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the next through disconnected workflows that result in knowledge loss during ea [...]